Integrichain Blog

Blog

Contracts & Pricing Gourab Khan
January 24, 2022

New Year, New Laws: Drug Price Reform, Coverage Gap, and 340B

4 Minute Read

Potential and pending regulatory changes in 2022 including the current status of the Build Back Better Act and Part D Benefit Design.

Pharmaceutical team discussing the future of the pharmaceutical industry

Corporate Kevin E. Leininger
January 20, 2022

IntegriChain and Blue Fin Group Combine Forces

2 Minute Read

Our newly combined team of commercialization experts focuses on solving your biggest access challenges: patient funnel pull-through and GTN optimization.

Pharma market access strategy for pre and post launch

Launch Readiness Leigh Anne Siino
January 19, 2022

Best Practices: Redesigning the Perfect Launch

3 Minute Read

We ask market access leaders what they would change if they had the ability to launch their therapy all over again.

Channel Aaron Light Umber Afshan
January 13, 2022

Frequently Asked Questions: Channel and Revenue Leakage

3 Minute Read

We discuss how life sciences manufacturers can maximize profit by reducing revenue leakage through actionable channel data insights.

Channel Olivia Nweze Tim Keys
December 20, 2021

Retail Pharmacy’s Digital Transformation

3 Minute Read

As society shifts toward digital and delivery-based economies, we ask: what will pharmacies look like in the future?

ICyte Platform Josh Halpern
November 23, 2021

A Look Back at the 2021 Access Insights Conference

2 Minute Read

Co-founder and EVP Josh Halpern reviews the recent Access Insights Conference and some of the key challenges that Life Sciences market access teams face.

Contracts & Pricing Brendan Crabtree
November 23, 2021

Regulatory Updates

4 Minute Read

This month we discuss COVID-19 vaccine mandates, the recent HHS drug discount ruling, and Medicare drug price reforms.

ICyte Platform Kevin E. Leininger
October 29, 2021

15 Years Strong

2 Minute Read

Founder and CEO Kevin Leininger celebrates IntegriChain's outstanding customers and our team of professionals around the globe on our 15th anniversary.

Contracts & Pricing Ben Fanelli Kevin Ehmann
October 20, 2021

The New Plan for Addressing High Drug Prices

4 Minute Read

We discuss the Biden administration's plan for combatting high drug prices, the new PBM public law reporting cycle, and MA and Part D rule for 2022.

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article